查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451670

2024-2032 年按類型、疾病類型、技術、配銷通路和地區分類的治療性疫苗市場報告

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2023年全球治療性疫苗市場規模達到313億美元。展望未來， IMARC Group預計到2032年市場規模將達到714億美元，2024-2032年複合年成長率（CAGR）為9.5%。治療選擇有限的疾病盛行率不斷上升，個人對微創手術（MIS）的偏好不斷增加，以及製藥公司、研究機構和學術界之間不斷加強的合作夥伴關係是推動市場的一些主要因素。

治療性疫苗，也稱為治療疫苗或免疫療法疫苗，是一種旨在刺激患者免疫系統針對和對抗特定疾病的醫療干預措施。與化療等傳統療法相比，它們的副作用更少。它們刺激免疫系統而不會對健康細​​胞造成廣泛損害。它們有助於降低初始治療後疾病復發的可能性。它們可以與其他治療方法（例如化療或標靶治療）結合使用，以產生協同效應。它們透過增強免疫反應來控制病毒量並最大限度地減少疾病進展，從而幫助管理人類免疫缺陷病毒 (HIV) 和乙型肝炎等慢性感染。

治療選擇有限的疾病（例如某些類型的癌症和罕見疾病）的盛行率不斷上升，正在催化對疫苗等創新治療方法的需求。此外，人口老化日益嚴重，極易患各種慢性疾病，這推動了對治療性疫苗等新型治療方式的需求。除此之外，各國政府正在為免疫療法和疫苗領域的研發提供支持性政策、補助和資金。此外，個人對非侵入性或微創治療方案的日益偏好正在推動對治療性疫苗的需求。此外，製藥公司、研究機構和學術界之間的合作正在加速治療性疫苗的開發和商業化。

治療疫苗市場趨勢/促進因素：

慢性病盛行率上升

癌症、自體免疫疾病和傳染病等各種慢性健康狀況的盛行率不斷上升，是推動市場成長的關鍵因素之一。治療性疫苗透過利用個體的免疫系統來識別和靶向疾病相關抗原，提供了一條有前途的途徑。除此之外，對個人化藥物日益成長的偏好正在對市場產生正面影響。這些疫苗有潛力針對特定疾病並徹底改變疾病管理。此外，治療性疫苗可以降低疾病復發的風險，並提高患者的治療效果和生活品質。

免疫學和生物技術的進步

免疫學和生物技術的快速進步正在創造積極的市場前景。這些科學進步正在重新定義我們對免疫系統及其對疾病反應的理解。此外，免疫學的突破揭示了免疫檢查點、細胞激素訊號傳導和抗原呈現的複雜性，為推動更有效的治療性疫苗的開發提供了見解。除此之外，生物技術創新，包括基於 mRNA 的疫苗平台和基因編輯技術，正在重新構想疫苗設計和生產的格局。此外，基於奈米顆粒的疫苗的出現提供了控制抗原呈現的機會，放大了免疫反應以提高治療效果。

轉向精準醫療

向精準醫療的轉變正在積極影響治療性疫苗市場。精準醫學體現了以患者為中心的方法，根據個別特徵（如遺傳學、分子譜和免疫標記）客製化治療方案。這種方法承認每位患者疾病的獨特性，並尋求最佳化治療結果。除此之外，這些疫苗透過針對每位患者獨特的疾病特異性抗原來解決癌症等疾病固有的異質性。預測性生物標記的識別和創新生物標記引導策略的引入提高了積極反應的可能性，因為它們確定了最有可能從這些治療中受益的患者。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球治療疫苗市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 抗原疫苗
    • 市場走向
    • 市場預測
  • 樹突細胞疫苗
    • 市場走向
    • 市場預測
  • DNA疫苗
    • 市場走向
    • 市場預測
  • 腫瘤細胞疫苗
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依疾病類型

  • 自體免疫疾病疫苗
    • 市場走向
    • 市場預測
  • 成癮疫苗
    • 市場走向
    • 市場預測
  • 神經系統疾病疫苗
    • 市場走向
    • 市場預測
  • 傳染病疫苗
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依技術

  • 自體疫苗
    • 市場走向
    • 市場預測
  • 同種異體疫苗
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Agenus Inc.
    • Argos Therapeutics Inc.
    • Bavarian Nordic A/S
    • Cel-Sci Corporation
    • CSL Limited
    • Emergent Biosolutions Inc.
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A6496

The global therapeutic vaccines market size reached US$ 31.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 71.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.5% during 2024-2032. The rising prevalence of diseases with limited treatment options, increasing preferences of individuals for minimally invasive surgeries (MIS), and the growing partnerships between pharmaceutical companies, research institutions, and academia are some of the major factors propelling the market.

Therapeutic vaccines, also known as treatment vaccines or immunotherapeutic vaccines, are a type of medical intervention designed to stimulate the immune system of patients to target and combat specific diseases. They have fewer side effects compared to traditional treatments like chemotherapy. They stimulate the immune system without causing extensive damage to healthy cells. They help reduce the likelihood of disease recurrence after initial treatment. They can be combined with other treatments, such as chemotherapy or targeted therapies, to create a synergistic effect. They aid in managing chronic infections like human immunodeficiency viruses (HIV) and hepatitis B by enhancing the immune response to control the viral load and minimize disease progression.

The rising prevalence of diseases with limited treatment options, such as certain types of cancers and rare disorders, is catalyzing the demand for innovative therapeutic approaches like vaccines. Additionally, the increasing aging population aging population, which is highly susceptible to various chronic ailments is driving the need for novel treatment modalities like therapeutic vaccines. Apart from this, governments of various countries are offering supportive policies, grants, and funding for research and development (R&D) in the field of immunotherapy and vaccines. Furthermore, the rising preferences of individuals for non-invasive or minimally invasive treatment options are driving the demand for therapeutic vaccines. Moreover, partnerships between pharmaceutical companies, research institutions, and academia are accelerating the development and commercialization of therapeutic vaccines.

Therapeutic Vaccines Market Trends/Drivers:

Rising prevalence of chronic diseases

The rising prevalence of various chronic health conditions, such as cancer, autoimmune disorders, and infectious diseases represents one of the key factors propelling the market growth. Therapeutic vaccines offer a promising avenue by harnessing the immune system of individuals to recognize and target disease-associated antigens. Apart from this, rising preferences for personalized medicines is positively influencing the market. These vaccines hold the potential to target specific disorders and revolutionize disease management. Moreover, therapeutic vaccines can reduce the risk of disease recurrence, enhancing patient outcomes and quality of life.

Advancements in immunology and biotechnology

The rapid advancements in immunology and biotechnology are creating a positive market outlook. These scientific advancements are redefining our understanding of the immune system and its responses to diseases. Additionally, breakthroughs in immunology are unveiling the intricacies of immune checkpoints, cytokine signaling, and antigen presentation, providing insights that fuel the development of more effective therapeutic vaccines. Apart from this, biotechnology innovations, including mRNA-based vaccine platforms and gene editing techniques, are reimagining the landscape of vaccine design and production. Furthermore, the advent of nanoparticle-based vaccines offers opportunities for controlled antigen presentation, amplifying the immune reaction for heightened therapeutic efficacy.

Shift towards precision medicine

The shift towards precision medicine is positively influencing the therapeutic vaccines market. Precision medicine embodies a patient-centric approach, tailoring treatments to individual characteristics such as genetics, molecular profiles, and immunological markers. This approach acknowledges the uniqueness of the disease of each patient and seeks to optimize therapeutic outcomes. Apart from this, these vaccines address the inherent heterogeneity of diseases like cancer by targeting disease-specific antigens that are distinct to each patient. The identification of predictive biomarkers and the introduction of innovative biomarker-guided strategies enhance the likelihood of positive responses, as they identify patients who are most likely to benefit from these treatments.

Therapeutic Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global therapeutic vaccines market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, disease type, technology and distribution channel.

Breakup by Type:

Antigen Vaccines

Dendritic Cell Vaccine

DNA Vaccine

Tumor Cell Vaccines

Tumor cell vaccines hold the largest market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes antigen vaccines, dendritic cell vaccine, DNA vaccine, and tumor cell vaccines. According to the report, tumor cell vaccines represented the largest market segment as they are specifically designed to target cancer cells, offering a highly focused approach to treatment. This specificity minimizes damage to healthy cells, reducing adverse effects commonly associated with traditional therapies. Additionally, they stimulate the immune system to remember cancer cells, enabling the body to respond more effectively if the cancer recurs. This immune memory contributes to longer-lasting treatment outcomes. Apart from this, they can be used in combination with other treatments like checkpoint inhibitors or chemotherapy, creating a synergistic effect that enhances the overall treatment response. Furthermore, these vaccines help reduce the likelihood of tumor resistance that can occur with single-target therapies.

Breakup by Disease Type:

Autoimmune Disease Vaccines

Addiction Vaccine

Neurological Disease Vaccine

Infectious Disease Vaccine

Others

Autoimmune disease vaccines represent the largest market segment

A detailed breakup and analysis of the market based on the disease type has also been provided in the report. This includes autoimmune disease vaccines, addiction vaccines, neurological disease vaccine, infectious disease vaccine, and others. According to the report, autoimmune disease vaccines dominates the market due to the rising prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and lupus across the globe. Additionally, these vaccines offer a potential alternative by stimulating immune tolerance, reducing the need for immunosuppression. Apart from this, they can be customized based on individual patient profiles, considering genetic and immunological factors. This aligns with the growing trend towards personalized medicine, enhancing treatment effectiveness. Apart from this, positive outcomes from clinical trials of autoimmune disease vaccines, coupled with advancements in immunology research, validate their potential to address unmet medical needs.

Breakup by Technology:

Autologous Vaccines

Allogeneic Vaccine

Autologous vaccines account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on technology. This includes autologous vaccines and allogeneic vaccine. According to the report, autologous vaccines hold the largest market share as they are custom-made for each patient using their own cells, ensuring a personalized treatment strategy that aligns with the patient's unique disease profile and immune system. Apart from this, since autologous vaccines use the original cells of patients, there is a lower risk of immune rejection or adverse reactions compared to treatments that involve foreign agents. Furthermore, they help reduce toxicity concerns associated with traditional treatments like chemotherapy by targeting disease cells while sparing healthy cells. Moreover, autologous vaccines are well-suited to address the genetic and molecular heterogeneity often found in diseases like cancer.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies.

Hospital pharmacies operate within healthcare facilities, which ensures direct access to patients undergoing treatments. They facilitate immediate availability, expert guidance, and seamless integration with medical care and aid in dispensing and administering therapeutic vaccines, especially for critical conditions requiring close medical supervision.

Retail pharmacies are widespread and easily accessible to the general population. They offer convenience and a wide range of healthcare products, including therapeutic vaccines. Additionally, they cater to diverse patient needs, making therapeutic vaccines more accessible to the masses.

Online pharmacies offer a convenient platform to purchase therapeutic vaccines remotely. They provide a wide selection, price comparisons, and home delivery, which are particularly advantageous for patients with mobility limitations or those seeking privacy.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest therapeutic vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region has a well-developed healthcare infrastructure, comprising modern hospitals, research institutions, and pharmaceutical companies, which accelerates research, development, and commercialization of therapeutic vaccines. Additionally, North America is a global hub for medical research and innovation, housing renowned universities, research centers, and biotechnology firms. Apart from this, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug and vaccine approvals. Moreover, North America has a well-established clinical trial ecosystem, which facilitates the efficient testing and validation of therapeutic vaccines. The availability of diverse patient populations and expert medical professionals expedites the trial process.

Competitive Landscape:

Companies are investing in research to identify novel antigens and develop innovative vaccine platforms, which include exploring cutting-edge technologies like mRNA-based vaccines, viral vectors, and personalized vaccine approaches. Additionally, many vaccine developers are conducting rigorous clinical trials to evaluate the safety and efficacy of their products. Furthermore, they are working closely with regulatory agencies to obtain approvals for their therapeutic vaccines. This involves compiling comprehensive data from clinical trials to demonstrate safety, efficacy, and manufacturing quality. Moreover, many leading companies are investing in infrastructure and technologies to ensure consistent and efficient vaccine production.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agenus Inc.

Argos Therapeutics Inc.

Bavarian Nordic A/S

Cel-Sci Corporation

CSL Limited

Emergent Biosolutions Inc.

GSK plc

Merck & Co. Inc.

Pfizer Inc.

Sanofi S.A.

Recent Developments:

In July 2023, Sanofi S.A. announced that it has received marketing authorization for Dupixent(R) (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis.

In August 2023, the European Commission approved Pfizer Inc's ABRYSVO(TM) to help protect infants through maternal immunization and older adults from RSV.

In August 2023, Merck & Co. Inc. announced that LYNPARZA(R) (olaparib)Plus Abiraterone and Prednisolone are approved in Japan for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Key Questions Answered in This Report

  • 1. What was the size of the global therapeutic vaccines market in 2023?
  • 2. What is the expected growth rate of the global therapeutic vaccines market during 2024-2032?
  • 3. What are the key factors driving the global therapeutic vaccines market?
  • 4. What has been the impact of COVID-19 on the global therapeutic vaccines market?
  • 5. What is the breakup of the global therapeutic vaccines market based on the type?
  • 6. What is the breakup of the global therapeutic vaccines market based on the disease type?
  • 7. What is the breakup of the global therapeutic vaccines market based on the technology?
  • 8. What are the key regions in the global therapeutic vaccines market?
  • 9. Who are the key players/companies in the global therapeutic vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Therapeutic Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Antigen Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Dendritic Cell Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Vaccine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Tumor Cell Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Autoimmune Disease Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Addiction Vaccine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disease Vaccine
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infectious Disease Vaccine
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Autologous Vaccines
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Allogeneic Vaccine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Argos Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Bavarian Nordic A/S
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Cel-Sci Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 CSL Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Emergent Biosolutions Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GSK plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co. Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Therapeutic Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Therapeutic Vaccines Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Therapeutic Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Therapeutic Vaccines Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Therapeutic Vaccines Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Therapeutic Vaccines Market: Breakup by Technology (in %), 2023
  • Figure 7: Global: Therapeutic Vaccines Market: Breakup by Distribution Channel (in %), 2023
  • Figure 8: Global: Therapeutic Vaccines Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Therapeutic Vaccines (Antigen Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Therapeutic Vaccines (Antigen Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Therapeutic Vaccines (DNA Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Therapeutic Vaccines (DNA Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Therapeutic Vaccines (Addiction Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Therapeutic Vaccines (Addiction Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Therapeutic Vaccines (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Therapeutic Vaccines (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Therapeutic Vaccines (Autologous Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Therapeutic Vaccines (Autologous Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Therapeutic Vaccines (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Therapeutic Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Therapeutic Vaccines (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Therapeutic Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Therapeutic Vaccines (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Therapeutic Vaccines (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Therapeutic Vaccines Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Therapeutic Vaccines Industry: SWOT Analysis
  • Figure 87: Global: Therapeutic Vaccines Industry: Value Chain Analysis
  • Figure 88: Global: Therapeutic Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Therapeutic Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Therapeutic Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Therapeutic Vaccines Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Therapeutic Vaccines Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 5: Global: Therapeutic Vaccines Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Therapeutic Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Therapeutic Vaccines Market: Competitive Structure
  • Table 8: Global: Therapeutic Vaccines Market: Key Players